HOWL
Werewolf Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.97
+2.38%Margins
Gross margin
86.4%
EBITDA margin
-104.8%
EBIT margin
-121.8%
Net margin
-164.8%
FCF margin
-143.6%
-212.5%
Return on equity
-143.3%
Return on assets
-157.0%
Return on invested capital
0.51x
Asset turnover
-$30.1M
Cash from operations
$0.45
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026